Sponsor content
177 result(s) found, displaying 1 to 10
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Australian public assessment report (AusPar)Imdelltra (tarlatamab) has been provisionally approved for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
-
Mar-2026Prescription medicine evaluationActive ingredient: evolocumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 80mg/0.8mL injection solution syringe within a pen injector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 40mg/0.4mL injection solution syringe within a pen injector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 20mg/0.2mL injection solution syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 40mg/0.4mL injection solution syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IMDELLTRA tarlatamab 1 mg powder for injection vial with intravenous (IV) solution stabiliser vial composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IMDELLTRA tarlatamab 10 mg powder for injection vial with intravenous (IV) solution stabiliser vial composite pack.
-
Australian public assessment report (AusPar)Tepezza has been approved for the treatment of moderate to severe Thyroid Eye Disease.